PARP1 and ovarian carcinoma: Although PARP inhibitors changed importantly ovarian cancer treatment landscape, some challenges are still faced, especially in the way of improving PARP inhibitor efficacy in HR-proficient tumors and overcoming PARP resistance in HRD tumors.